Table 2. ELISpot responses to Ap8 and Ap10 peptide pools and individual 15mer peptides within each pool.
| Pool | 15mer | Sequence | v102 | v111 | v182 | V1563 | V1943 |
| Prot. | Prot. | Prot. | NP | Delay | |||
| Ap8 | 193 | 321 | 141 | 47 | |||
| A92 | EGFKNKNASMIKSAF | 1 | 0 | 0 | 4 | ||
| A93 | NKNASMIKSAFLPTG | 0 | 2 | 0 | 4 | ||
| A94 | SMIKSAFLPTGAFKA | 9 | 10 | 11 | 6 | ||
| A95 | SAFLPTGAFK ADRYK | 9 | 2 | 61 | 4 | ||
| A96 | PTGAFKADRYKSHGK | 1 | 2 | 0 | 3 | ||
| A97 | FKADRYKSHGKGYNW | 164 | 270 | 141 | 48 | ||
| A98 | RYKSHGKGYNW GNYN | 96 | 85 | 14 | 7 | ||
| A99 | HGKGYNWGNYNTETQ | 0 | 5 | 5 | 6 | ||
| A100 | YNWGNYNTETQKCEI | 1 | 5 | 0 | 6 | ||
| A101 | NYNTETQKCEIFNVK | 0 | 0 | 1 | 0 | ||
| A102 | ETQKCEIFNVKPTCL | 0 | 0 | 0 | 6 | ||
| A103 | CEIFNVKPTCLINNS | 1 | 0 | 1 | 1 | ||
| A104 | NVKPTCLINNSSYIA | 3 | 0 | 0 | 0 | ||
| Ap10 | 159 | ||||||
| A118 | EGNKKIIAPRIFISD | 2 | |||||
| A119 | KIIAPRIFISDDKDS | 0 | |||||
| A120 | PRIFISDDKDSLKCP | 1 | |||||
| A121 | ISDDKDSLKCPCDPE | 3 | |||||
| A122 | KDSLKCPCDPEMVSN | 2 | |||||
| A123 | KCPCDPEMVSNSTCR | 1 | |||||
| A124 | DPEMVSNSTCRFFVC | 0 | |||||
| A125 | VSNSTCRFFVCK CVE | 140 | |||||
| A126 | TCRFFVCKCVERRAE | 9 | |||||
| A127 | FVCKCVERRAEVTSN | 4 | |||||
| A128 | CVERRAEVTSNNEVV | 10 | |||||
| A129 | RAEVTSNNEVVVKEE | 0 | |||||
| A130 | TSNNEVVVKEEYKDE | 0 |
1
DNA/Ad cells collected 28 days after malaria challenge;
2
DNA/Ad cells collected 84 days after malaria challenge.
3
AdCA cells collected 2 months after the malaria challenge. Prot. = Protected. NP = Not Protected. All 15mer peptides within Ap8 and Ap10 were tested with DNA/Ad, and AdCA-immunized volunteers in ELISpot assays. Positive activities (bold): activity was greater than twice that of control, and the difference in absolute count was >10 sfc/m. Predicted epitopes within positive 15mers are shown in bold and underlined.